Cited 3 time in
- Immunotherapy in hematologic malignancies: emerging therapies and novel approaches
- Ji Yoon Noh; H Seo; Jung Woon Lee; Haiyoung Jung
- Bibliographic Citation
- International Journal of Molecular Sciences, vol. 21, no. 21, pp. 8000-8000
- Publication Year
- Immunotherapy is extensively investigated for almost all types of hematologic tumors, from preleukemic to relapse/refractory malignancies. Due to the emergence of technologies for target cell characterization, antibody design and manufacturing, as well as genome editing, immunotherapies including gene and cell therapies are becoming increasingly elaborate and diversified. Understanding the tumor immune microenvironment of the target disease is critical, as is reducing toxicity. Although there have been many successes and newly FDA-approved immunotherapies for hematologic malignancies, we have learned that insufficient efficacy due to disease relapse following treatment is one of the key obstacles for developing successful therapeutic regimens. Thus, combination therapies are also being explored. In this review, immunotherapies for each type of hematologic malignancy will be introduced, and novel targets that are under investigation will be described.
- hematologic malignancy; immune checkpoint; chimeric antigen receptor; lymphocyte; antibody？drug conjugate
- Appears in Collections:
- Division of Biomedical Research > Immunotherapy Research Center > 1. Journal Articles
Division of Research on National Challenges > Environmental diseases research center > 1. Journal Articles
- Files in This Item:
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.